FITC-Labeled Recombinant Human ERBB1/HER1/EGFR (25-378) Protein
The FITC-Labeled Recombinant Human ERBB1/HER1/EGFR (25-378) Protein is a biologically active recombinant protein that plays a significant role in various cellular processes and signaling pathways in human biology. This protein is widely employed in immunological research, cell biology studies, protein-protein interaction analyses, and therapeutic development, providing researchers with a reliable tool for investigating FITC-Labeled ERBB1/HER1/EGFR (25-378) function and its implications in health and disease.
This product (SKU: RPCB0578) is produced using advanced expression systems and features a C-His&Avi tag for convenient detection and purification. The protein exhibits a calculated molecular weight of 41.6 kDa with an observed molecular weight of 68-80 kDa under denaturing conditions, achieving ≥ 95 % as determined by SDS-PAGE., ensuring exceptional quality and consistency for research applications.
Key Features
High Purity by Affinity Chromatography
Mammalian & Bacterial Expression Systems
High lot-to-lot consistency via strict QC
Product Name:
FITC-Labeled Recombinant Human ERBB1/HER1/EGFR (25-378) Protein
High quality, high purity and low endotoxin recombinant FITC-Labeled Recombinant Human HER1/ERBB1/EGFR (25-378) Protein (RP00500FLQ), tested reactivity in HEK293 cells and has been validated in SDS-PAGE.100% guaranteed.
Endotoxin:
< 1 EU/μg of the protein by LAL method.
Purity:
≥ 95 % as determined by SDS-PAGE.
Formulation:
Supplied as 0.22 μm filtered solution in PBS (pH 7.4).
Storage:
Store at -70℃. This product is stable at ≤ -70℃ for up to 1 year from the date of receipt. For optimal storage, aliquot into smaller quantities after centrifugation and store at recommended temperature. Avoid repeated freeze-thaw cycles.
The epidermal growth factor receptor (EGFR) is overexpressed in a variety of human epithelial tumors, often as a consequence of gene amplification. Tumors with EGFR gene amplification frequently contain EGFR gene rearrangements, with the most common extracellular domain mutation being EGFRvIII. This mutation leads to a deletion of exons 2-7 of the EGFR gene and renders the mutant receptor incapable of binding any known ligand.
FITC-Labeled Recombinant Human HER1/ERBB1/EGFR (25-378) Protein was determined by Tris-Bis PAGE under reducing conditions.
FACS Analysis of Anti-EGFRVIII CAR Expression. 293T cells were transfected with anti-EGFRVIII-scFv and His tag. Cells were incubated with 5 μg/mL FITC-Labeled Human EGFRVIII, His Tag and FITC-labeled protein control. Non-transfected 293T cells and FITC-labeled protein control were used as negative control.
